Recommendations  Strength rating,
First-line treatment for cisplatin-eligible patients,
New 2023 recommendation: Offer platinum combination chemotherapy to platinum-  Strong  eligible patients.,
First-line treatment in patients ineligible for cisplatin or carboplatin,
New 2023 recommendation: Offer gemcitabine/carboplatin chemotherapy to   cisplatin-ineligible patients.,Strong
2022 recommendation: Offer checkpoint inhibitors pembrolizumab or atezolizumab   depending on PD-L1 status.,Weak
Revised 2023 recommendation: Offer checkpoint inhibitors pembrolizumab or   atezolizumab to patients with PD-L1 positive tumours.,Weak
Second-line treatment,
New 2023 recommendation: Offer enfortumab vedotin to patients previously treated   with platinum-containing chemotherapy and who had disease progression during or   after treatment with a PD-1 or PD-L1 inhibitor.,Strong
2022 recommendation: Offer erdafitinib in platinum-refractory tumours with FGFR   alterations.,Strong
Revised 2023 recommendation: Offer erdafitinib as subsequent-line therapy   to platinum-refractory patients with FGFR DNA genomic alterations (FGFR2/3   mutations or FGFR3 fusions).,Weak
